The team is developing a powerful new tool to help fight stomach cancer

A powerful new tool to fight the bacteria that cause cancer in our stomach

Clinical test for antimicrobial susceptibility Ramanometry for Helicobacter pylori (CAST-R-HP). Credit: Liu Yang

Helicobacter pylori (H. pylori), a bacterium that can cause human gastritis, peptic ulcer and stomach cancer, infects about half of the world’s population. It is important to quickly identify the infection and choose the right combination of sensitive antibiotics. However, current tools are limited, mainly because H. pylori is slow-growing and difficult to cultivate.

Researchers from the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences (CAS) and their collaborators at the State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Infectious Disease Control and Prevention (ICDC) of China CDC and Qingdao Municipal Hospital have developed a medical tool called Clinical Antimicrobial Susceptibility Ramanometry for Helicobacter pylori (CAST-R-HP), which promises to be a powerful new tool in the diagnosis and treatment of H. pylori infections.

Their findings were published on June 18 in the journal Clinical Chemistry.

In the fight against H. pylori, researchers and health professionals need tools that are fast, reliable and sensitive to identify pathogens and antimicrobial susceptibility testing, along with profiling a mutation throughout the genome that reveals bacteriamechanisms of resistance.

Modern methods for detecting H. pylori and identifying sensitive antibiotics for eradication therapy are bacterial culture and susceptibility testing for drugs based on endoscopic samples of gastric mucosa.

“The current culture-based antimicrobial susceptibility testing is too slow and requires at least a week to complete,” said Prof. Zhang Jiangong of the State Key Laboratory for Infectious Disease Prevention and Control, ICDC of China CDC, senior author of the study.

The team has developed an approach that performs rapid identification of pathogens based on inhibition of metabolism by antimicrobial susceptibility tests and high-quality single-cell sequencing of the entire genome to reveal mechanisms of antimicrobial resistance. Their approach provides more than 98 percent accuracy and is successful with a precise resolution of a cell operating directly from biopsy specimens.

The core technologies, called D2O-Sampling Ramanometry and Raman-Activated Cell Sorting and Sequencing (RACS-Seq), are integrated into the CAST-R-HP tool.

“Culture independence, speed, high resolution, and comprehensive information output suggest CAST-R-HP as a powerful tool for diagnosing and treating H. pylori infections, now with single-cell precision,” said Xu Jian, another senior author of the study. and director of the single-cell center at QIBEBT.

Looking ahead to future research, the team will explore ways to further accelerate CAST-R-HP, for example by developing a microfluidic chip to enrich cell traces directly from H. pylori-infected biopsy tissue. This chip development can further reduce the time to perform the antimicrobial susceptibility test based on metabolic inhibition from approximately three days to less than 24 hours.

“Our next step would be to fully appreciate the usefulness of the workflow for all first- and second-line antibiotics used to treat H. pylori infections,” said Liu Ming of the Single Cell Center at QIBEBT, the first author of the paper. .

The short CAST-R-HP can also be used to map H. pylori heterogeneity at the genome level. “By enabling identification, drug susceptibility testing, and tracing of a genome-based source at a single cell resolution, CAST-R-HP should not only facilitate the accurate administration of H. pylori antibiotics. infectionbut reduce the risk of drug resistance in general human populations, “added Sue Jian.


The automated CAST-R system helps identify the best antimicrobials to fight acute blood infections


More info:
Min Liu et al, Single cell identification, drug susceptibility testing and sequencing of the entire Helicobacter pylori genome directly from gastric biopsy by clinical antimicrobial susceptibility test Ramanometry, Clinical Chemistry (2022). DOI: 10.1093 / clinchem / hvac082

Quote: The team is developing a powerful new tool to help fight stomach-causing bacteria (2022, June 20, 2022), retrieved on June 20, 2022 from https://phys.org/news/2022-06- team-powerful-tool-aid -cancer-causing.html

This document is subject to copyright. Except for any fair transaction for the purpose of private research or study, no part may be reproduced without written permission. The content is provided for informational purposes only.

Related Posts

Leave a Reply

Your email address will not be published.